Thermal proteome profiling identifies PIP4K2A and ZADH2 as off‐targets of Polo‐like kinase 1 inhibitor volasertib-Reference-Cited by-同舟云学术

Thermal proteome profiling identifies PIP4K2A and ZADH2 as off‐targets of Polo‐like kinase 1 inhibitor volasertib

Published:2021-06-18 Issue:7 Volume:35 Page:
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:The FASEB Journal

Author:

Goroshchuk Oksana¹,Kolosenko Iryna¹,Kunold Elena²,Vidarsdottir Linda¹,Pirmoradian Mohammad²,Azimi Alireza¹,Jafari Rozbeh²^ORCID,Palm‐Apergi Caroline¹^ORCID

Affiliation:

1. Department of Laboratory Medicine, Biomolecular and Cellular Medicine Karolinska Institutet Solna Sweden

2. Department of Oncology‐Pathology Clinical Proteomics Mass Spectrometry Karolinska Institutet Solna Sweden

Funder

Åke Wiberg Stiftelse

Dr Åke Olssons Stiftelse för Haematologisk Forskning

Karolinska Institutet

Magnus Bergvalls Stiftelse

Robert Lundbergs Minnesstiftelse

Vetenskapsrådet

Cancerfonden

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202100457RR

Reference65 articles.

1. Polo-like kinases and acute leukemia

2. Impairments that Influence Physical Function among Survivors of Childhood Cancer

3. From Plk1 to Plk5

4. Small-molecule inhibitors for targeting polo-like kinase 1

5. Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting polo-like kinase 1: advancements and future directions in anti-cancer drug discovery;Expert Opinion on Drug Discovery;2024-07-29

2. How mass spectrometry can be exploited to study AMPK;Essays in Biochemistry;2024-07-26

3. Development of Proteomics and Its Use in Acute Myeloid Leukemia;Advances in Clinical Medicine;2024

4. PLK4, a potential target against AML;Blood;2023-12-07

5. The pharmacologic and toxicologic characterization of the potent and selective KRAS G12D inhibitors ERAS-4693 and ERAS-5024;Toxicology and Applied Pharmacology;2023-09